Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial - PubMed (original) (raw)
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Diane M Harper et al. Lancet. 2006.
Free article
Abstract
Background: Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. Our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent HPV-16/18 L1 virus-like particle AS04 vaccine against incident and persistent infection with HPV 16 and HPV 18 and their associated cytological and histological outcomes.
Methods: We did a follow-up study of our multicentre, double-blind, randomised, placebo-controlled trial reported in 2004. We included women who originally received all three doses of bivalent HPV-16/18 virus-like particle AS04 vaccine (0.5 mL; n=393) or placebo (n=383). We assessed HPV DNA, using cervical samples, and did yearly cervical cytology assessments. We also studied the long-term immunogenicity and safety of the vaccine.
Findings: More than 98% seropositivity was maintained for HPV-16/18 antibodies during the extended follow-up phase. We noted significant vaccine efficacy against HPV-16 and HPV-18 endpoints: incident infection, 96.9% (95% CI 81.3-99.9); persistent infection: 6 month definition, 94.3 (63.2-99.9); 12 month definition, 100% (33.6-100). In a combined analysis of the initial efficacy and extended follow-up studies, vaccine efficacy of 100% (42.4-100) against cervical intraepithelial neoplasia (CIN) lesions associated with vaccine types. We noted broad protection against cytohistological outcomes beyond that anticipated for HPV 16/18 and protection against incident infection with HPV 45 and HPV 31. The vaccine has a good long-term safety profile.
Interpretation: Up to 4.5 years, the HPV-16/18 L1 virus-like particle AS04 vaccine is highly immunogenic and safe, and induces a high degree of protection against HPV-16/18 infection and associated cervical lesions. There is also evidence of cross protection.
Similar articles
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G; GlaxoSmithKline HPV Vaccine Study Group. Harper DM, et al. Lancet. 2004 Nov 13-19;364(9447):1757-65. doi: 10.1016/S0140-6736(04)17398-4. Lancet. 2004. PMID: 15541448 Clinical Trial. - Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C, Tsang SH, Herrero R, Guillén D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, Schiller JT, Schiffman M, Schussler J, Gail MH, Quint W, Ocampo R, Morales J, Rodríguez AC, Hu S, Sampson JN, Kreimer AR; Costa Rica Vaccine Trial Group. Porras C, et al. Lancet Oncol. 2020 Dec;21(12):1643-1652. doi: 10.1016/S1470-2045(20)30524-6. Lancet Oncol. 2020. PMID: 33271093 Free PMC article. Clinical Trial. - Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G; HPV PATRICIA study group. Paavonen J, et al. Lancet. 2007 Jun 30;369(9580):2161-2170. doi: 10.1016/S0140-6736(07)60946-5. Lancet. 2007. PMID: 17602732 Clinical Trial. - Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L, Hopkins L, Hutton B, Fergusson D. Rambout L, et al. CMAJ. 2007 Aug 28;177(5):469-79. doi: 10.1503/cmaj.070948. Epub 2007 Aug 1. CMAJ. 2007. PMID: 17671238 Free PMC article. Review.
Cited by
- VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.
Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B. Tumban E, et al. PLoS One. 2012;7(11):e49751. doi: 10.1371/journal.pone.0049751. Epub 2012 Nov 19. PLoS One. 2012. PMID: 23185426 Free PMC article. - Human papillomavirus vaccine and systemic lupus erythematosus.
Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, Doria A, Shoenfeld Y. Gatto M, et al. Clin Rheumatol. 2013 Sep;32(9):1301-7. doi: 10.1007/s10067-013-2266-7. Epub 2013 Apr 28. Clin Rheumatol. 2013. PMID: 23624585 - Cutaneous infections and infestations: new therapies.
Keller EC, Tomecki KJ. Keller EC, et al. J Clin Aesthet Dermatol. 2011 Dec;4(12):18-24. J Clin Aesthet Dermatol. 2011. PMID: 22191004 Free PMC article. - Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter.
Mariz FC, Coimbra EC, Jesus AL, Nascimento LM, Torres FA, Freitas AC. Mariz FC, et al. Biomed Res Int. 2015;2015:594120. doi: 10.1155/2015/594120. Epub 2015 May 18. Biomed Res Int. 2015. PMID: 26090426 Free PMC article. - HPV-vaccination against cervical carcinoma: will it really work?
Gross G. Gross G. Med Microbiol Immunol. 2007 Sep;196(3):121-5. doi: 10.1007/s00430-007-0039-0. Epub 2007 Feb 21. Med Microbiol Immunol. 2007. PMID: 17318575 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources